YD Bio maintains a 0% debt-to-equity ratio, though the presence of outstanding warrants introduces a material risk of future share dilution for current investors.
| Metric | Dec'24 | Dec'23 |
|---|
| Total Current Assets | 3.47M | 271.72K |
| Cash & Short-Term Investments | 3.13M | 87.1K |
| Cash Only | 3.13M | 87.1K |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 262.8K | 98.43K |
| Days Sales Outstanding | 187.95 | 102.61 |
| Inventory | 37.34K | 69.4K |
| Days Inventory Outstanding | 38.39 | 128.8 |
| Other Current Assets | 0 | 0 |
| Total Non-Current Assets | 3.4M | 49.49K |
| Property, Plant & Equipment | 88.08K | 14.3K |
| Fixed Asset Turnover | 5.79x | 24.48x |
| Goodwill | 0 | 0 |
| Intangible Assets | 2.68M | 0 |
| Long-Term Investments | 0 | 10.62K |
| Other Non-Current Assets | 628.23K | 0 |
| Total Assets | 6.86M | 321.21K |
| Asset Turnover | 0.07x | 1.09x |
| Asset Growth % | 2036.98% | - |
| Total Current Liabilities | 263.06K | 298.22K |
| Accounts Payable | 26.74K | 17.98K |
| Days Payables Outstanding | 27.5 | 33.36 |
| Short-Term Debt | 290 | 34.32K |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | 0 | 344 |
| Current Ratio | 13.18x | 0.91x |
| Quick Ratio | 13.04x | 0.68x |
| Cash Conversion Cycle | 198.84 | 198.05 |
| Total Non-Current Liabilities | 10.92K | 0 |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 5.68K | 0 |
| Deferred Tax Liabilities | 1.46K | 0 |
| Other Non-Current Liabilities | 3.77K | 0 |
| Total Liabilities | 273.98K | 298.22K |
| Total Debt | 22.55K | 47.58K |
| Net Debt | -3.11M | -39.52K |
| Debt / Equity | 0.00x | 2.07x |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | -1893.69x | -4.59x |
| Total Equity | 6.59M | 22.99K |
| Equity Growth % | 28560.72% | - |
| Book Value per Share | - | - |
| Total Shareholders' Equity | 6.59M | 22.99K |
| Common Stock | 144.18K | 105.2K |
| Retained Earnings | -1.93M | -515.48K |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 45.07K | 47.21K |
| Minority Interest | 0 | 0 |
Rapid Cash Runway Depletion
According to recent financial disclosures, YD Bio maintains a cash position of $3.1M, which, when evaluated against its high-burn R&D-focused operating model, suggests a precarious liquidity buffer that may necessitate external capital infusion within the next 12 to 18 months to sustain ongoing clinical development activities.
The current cash balance appears insufficient to support the company's dual-track strategy of cancer diagnostics and regenerative ophthalmology over the long term. Investors should monitor the burn rate closely, as the lack of recurring revenue streams places the firm in a vulnerable position regarding its ability to fund operations without dilutive financing.
Based on reported figures, YD Bio maintains a 0% debt-to-equity ratio, indicating that the company has avoided leverage during its initial setup phase, which may provide a degree of strategic optionality as it navigates the high-risk, capital-intensive environment of early-stage biotechnology research and development.
While the absence of debt is a positive indicator of fiscal discipline, it also reflects the reality that the company likely lacks the cash flow durability required to service traditional debt obligations. The firm's reliance on equity-based funding appears to be a necessity rather than a strategic choice given its current pre-profit status.
As suggested by the 'W' suffix in the ticker symbol, the presence of outstanding warrants introduces a significant potential for future share count dilution, which warrants further investigation by investors concerned about the long-term impact on earnings per share and overall equity quality for existing shareholders.
The equity structure appears heavily influenced by the need to attract speculative capital, which may lead to substantial dilution if these warrants are exercised. This potential for increased share count could complicate future valuation metrics and should be factored into any assessment of the company's long-term capital structure.
Based on the company's February 2024 incorporation, the reported financial data may obscure the true extent of cash burn by potentially including non-recurring government grants or subsidies that do not reflect sustainable commercial product-market fit for its diagnostic kits, according to recent industry analysis.
The reliance on non-commercial revenue sources may mask the underlying operational weakness of the business model. Analysts should remain cautious, as the current balance sheet may not accurately reflect the company's ability to generate organic, self-sustaining cash flow once these initial subsidies are exhausted.
Quick answers to the most common questions about buying YDESW stock.
As of 2024, YD Bio Limited Warrants (YDESW) had total assets of $6.9M including $3.5M in current assets.
YD Bio Limited Warrants (YDESW) carries total debt of $0.0M, offset by $3.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
YD Bio Limited Warrants (YDESW) has total shareholders' equity (book value) of $6.6M. Book value represents the net worth of the company belonging to common stock holders.
YD Bio Limited Warrants (YDESW) reported a current ratio of 13.18x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.